{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:10:13Z","timestamp":1793293813800,"version":"4.5.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtos.2025.07.010","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:15:53Z","timestamp":1753888553000},"page":"302-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Topical pharmacologic treatments for dry eye disease: A systematic review"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3986-6552","authenticated-orcid":false,"given":"Louis","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsun","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"G\u00fcm\u00fc\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M.","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Ben\u00edtez-del-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Labetoulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Periman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtos.2025.07.010_bib1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.07.010_bib2","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/OPTH.S89700","article-title":"Associations between signs and symptoms of dry eye disease: a systematic review","volume":"9","author":"Bartlett","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2025.07.010_bib3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jtos.2015.11.002","article-title":"Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review","volume":"14","author":"McDonald","year":"2016","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.07.010_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jtos.2021.05.006","article-title":"The physical and mental burden of dry eye disease: a large population-based study investigating the relationship with health-related quality of life and its determinants","volume":"21","author":"Morthen","year":"2021","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2025.07.010_bib5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"issue":"10","key":"10.1016\/j.jtos.2025.07.010_bib6","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/j.bbamem.2016.02.020","article-title":"Tear film lipid layer: a molecular level view","volume":"1858","author":"Cwiklik","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.jtos.2025.07.010_bib7","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.survophthal.2022.01.010","article-title":"Metabolomics and lipidomics approaches in human tears: a systematic review","volume":"67","author":"Khanna","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jtos.2025.07.010_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108115","article-title":"Biological functions of tear film","volume":"197","author":"Pflugfelder","year":"2020","journal-title":"Exp Eye Res"},{"issue":"5","key":"10.1016\/j.jtos.2025.07.010_bib9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/ICO.0b013e318225415a","article-title":"Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study","volume":"31","author":"Lemp","year":"2012","journal-title":"Cornea"},{"issue":"7","key":"10.1016\/j.jtos.2025.07.010_bib10","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1167\/iovs.09-4445","article-title":"Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in Singapore","volume":"51","author":"Tong","year":"2010","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.jtos.2025.07.010_bib11","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1111\/aos.13732","article-title":"The prevalence of meibomian gland dysfunction, tear film and ocular surface parameters in an Austrian dry eye clinic population","volume":"96","author":"Rabensteiner","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2025.07.010_bib12","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40123-023-00669-1","article-title":"Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape","volume":"12","author":"Sheppard","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"10.1016\/j.jtos.2025.07.010_bib13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/bjophthalmol-2015-307415","article-title":"Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction","volume":"100","author":"Baudouin","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2025.07.010_bib14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II diagnostic methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.07.010_bib15","doi-asserted-by":"crossref","DOI":"10.5596\/c14-016","article-title":"Product review: Covidence (systematic review software)","volume":"35","author":"Babineau","year":"2014","journal-title":"J Can Health Libr Assoc"},{"issue":"3","key":"10.1016\/j.jtos.2025.07.010_bib16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.jtos.2025.07.010_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/JLB.5MIR0420-055R","article-title":"Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy","volume":"108","author":"Bendickova","year":"2020","journal-title":"J Leukoc Biol"},{"issue":"11","key":"10.1016\/j.jtos.2025.07.010_bib18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","article-title":"Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes","volume":"118","author":"Kunert","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.jtos.2025.07.010_bib19","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1167\/iovs.13-11681","article-title":"Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin A","volume":"54","author":"Gao","year":"2013","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2025.07.010_bib20","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.2147\/OPTH.S279051","article-title":"A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments","volume":"14","author":"Periman","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2025.07.010_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jtos.2019.12.006","article-title":"Immune - goblet cell interaction in the conjunctiva","volume":"18","author":"Alam","year":"2020","journal-title":"Ocul Surf"},{"issue":"5","key":"10.1016\/j.jtos.2025.07.010_bib22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"The cyclosporin A phase 2 study group. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.jtos.2025.07.010_bib23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.jtos.2025.07.010_bib24","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1185\/030079905X50615","article-title":"The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca","volume":"21","author":"Stonecipher","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.jtos.2025.07.010_bib25","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/archopht.126.8.1046","article-title":"Evaluation of topical cyclosporine for the treatment of dry eye disease","volume":"126","author":"Perry","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2025.07.010_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/ICL.0b013e3180676d44","article-title":"Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes","volume":"34","author":"Willen","year":"2008","journal-title":"Eye Contact Lens"},{"issue":"10","key":"10.1016\/j.jtos.2025.07.010_bib27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/ICO.0b013e318206caee","article-title":"The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy","volume":"30","author":"Su","year":"2011","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.jtos.2025.07.010_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jop.2009.0145","article-title":"A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial","volume":"26","author":"Chen","year":"2010","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"6","key":"10.1016\/j.jtos.2025.07.010_bib29","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3341\/kjo.2011.25.6.369","article-title":"Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance study","volume":"25","author":"Byun","year":"2011","journal-title":"Kor J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2025.07.010_bib30","doi-asserted-by":"crossref","DOI":"10.1080\/2331205X.2017.1321869","article-title":"Efficacy of topical carboxymethyl cellulose 0.5% and cyclosporine A 0.05% in dry eye syndrome","volume":"4","author":"Shah","year":"2017","journal-title":"Cogent Med"},{"key":"10.1016\/j.jtos.2025.07.010_bib31","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2147\/OPTH.S175065","article-title":"A phase II\/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease","volume":"12","author":"Tauber","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2025.07.010_bib32","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.2147\/OPTH.S392315","article-title":"Effect of OTX-101 in patients with dry eye disease at day 14 of treatment: ocular surface endpoint results from the phase 2b\/3 clinical trial","volume":"16","author":"Schechter","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2025.07.010_bib33","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease","volume":"126","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2025.07.010_bib34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/OPTH.S279364","article-title":"Phase 3 efficacy (worse-eye analysis) and long-term safety evaluation of OTX-101 in patients with keratoconjunctivitis sicca","volume":"15","author":"Sheppard","year":"2021","journal-title":"Clin Ophthalmol"},{"issue":"28","key":"10.1016\/j.jtos.2025.07.010_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3126\/nepjoph.v14i2.38928","article-title":"Safety and efficacy of cyclosporine (0.05% versus 0.09%) in dry eye disease. Is it the strength of cyclosporin that really matters?","volume":"14","author":"Rajpoot","year":"2022","journal-title":"Nepal J Ophthalmol"},{"issue":"7","key":"10.1016\/j.jtos.2025.07.010_bib36","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1089\/jop.2018.0154","article-title":"Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on conjunctival staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b\/3 and 3 clinical trials","volume":"35","author":"Smyth-Medina","year":"2019","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"10","key":"10.1016\/j.jtos.2025.07.010_bib37","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/ICO.0000000000001989","article-title":"Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b\/3 and phase 3 studies","volume":"38","author":"Malhotra","year":"2019","journal-title":"Cornea"},{"issue":"suppl 1","key":"10.1016\/j.jtos.2025.07.010_bib38","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/ICL.0000000000000636","article-title":"Efficacy and safety of OTX-101, a novel nanomicellar formulation of cyclosporine A, for the treatment of keratoconjunctivitis sicca: pooled analysis of a phase 2b\/3 and phase 3 study","volume":"46","author":"Sheppard","year":"2020","journal-title":"Eye Contact Lens"},{"issue":"2","key":"10.1016\/j.jtos.2025.07.010_bib39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/02713683.2021.1966477","article-title":"The effect of OTX-101 on tear production in patients with severe tear-deficient dry eye disease: a pooled analysis of phase 2b\/3 and phase 3 studies","volume":"47","author":"Toyos","year":"2022","journal-title":"Curr Eye Res"},{"issue":"4","key":"10.1016\/j.jtos.2025.07.010_bib40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2025.07.010_bib41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5301\/ejo.5000952","article-title":"A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye","volume":"27","author":"Baudouin","year":"2017","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2025.07.010_bib42","doi-asserted-by":"crossref","first-page":"678","DOI":"10.5301\/ejo.5001002","article-title":"One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease","volume":"27","author":"Baudouin","year":"2017","journal-title":"Eur J Ophthalmol"},{"issue":"11","key":"10.1016\/j.jtos.2025.07.010_bib43","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.clinthera.2018.09.012","article-title":"Persistence of efficacy of 0.1% cyclosporin A cationic emulsion in subjects with severe keratitis due to dry eye disease: a nonrandomized, open-label extension of the SANSIKA study","volume":"40","author":"Labetoulle","year":"2018","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.jtos.2025.07.010_bib44","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40123-022-00487-x","article-title":"Real-world effectiveness, tolerability and safety of cyclosporine A 0.1% cationic emulsion in severe keratitis and dry eye treatment","volume":"11","author":"Geerling","year":"2022","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10.1016\/j.jtos.2025.07.010_bib45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/bjophthalmol-2017-311801","article-title":"Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies","volume":"103","author":"Leonardi","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2025.07.010_bib46","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","article-title":"A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease","volume":"126","author":"Wirta","year":"2019","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.jtos.2025.07.010_bib47","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/ICO.0000000000002633","article-title":"A water-free 0.1% cyclosporine A solution for treatment of dry eye disease: results of the randomized phase 2B\/3 ESSENCE study","volume":"40","author":"Sheppard","year":"2021","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.jtos.2025.07.010_bib48","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaophthalmol.2023.0709","article-title":"Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial","volume":"141","author":"Akpek","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"31","key":"10.1016\/j.jtos.2025.07.010_bib49","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016710","article-title":"Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: a 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine (Baltim)"},{"issue":"5","key":"10.1016\/j.jtos.2025.07.010_bib50","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41433-023-02807-2","article-title":"Exploration of efficacy and mechanism of 0.05% cyclosporine eye drops (II) monotherapy in allergic conjunctivitis-associated dry eye","volume":"38","author":"Jiao","year":"2023","journal-title":"Eye (Lond)"},{"issue":"7","key":"10.1016\/j.jtos.2025.07.010_bib51","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1089\/jop.2016.0164","article-title":"Evaluation of clinical efficacy and safety of a novel cyclosporin A nanoemulsion in the treatment of dry eye syndrome","volume":"33","author":"Kim","year":"2017","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"4","key":"10.1016\/j.jtos.2025.07.010_bib52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3341\/kjo.2018.0116","article-title":"Efficacy of topical cyclosporine nanoemulsion 0.05% compared with topical cyclosporine emulsion 0.05% and diquafosol 3% in dry eye","volume":"33","author":"Park","year":"2019","journal-title":"Kor J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2025.07.010_bib53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12886-023-02838-z","article-title":"Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial","volume":"23","author":"Rao","year":"2023","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2025.07.010_bib54","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ajo.2011.11.003","article-title":"A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye","volume":"153","author":"Semba","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2025.07.010_bib55","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.jtos.2025.07.010_bib56","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jtos.2025.07.010_bib57","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.jtos.2025.07.010_bib58","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/ICO.0000000000000803","article-title":"Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study","volume":"35","author":"Donnenfeld","year":"2016","journal-title":"Cornea"},{"issue":"10","key":"10.1016\/j.jtos.2025.07.010_bib59","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1080\/03007995.2016.1210107","article-title":"Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials","volume":"32","author":"Holland","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"10.1016\/j.jtos.2025.07.010_bib60","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jamaophthalmol.2021.3943","article-title":"Efficacy of lifitegrast ophthalmic solution, 5.0%, in patients with moderate to severe dry eye disease: a post hoc analysis of 2 randomized clinical trials","volume":"139","author":"Holland","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2025.07.010_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jtos.2016.01.001","article-title":"Lifitegrast, a novel integrin antagonist for treatment of dry eye disease","volume":"14","author":"Perez","year":"2016","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2025.07.010_bib62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/jop.2019.0060","article-title":"The immunological basis of dry eye disease and current topical treatment options","volume":"36","author":"Periman","year":"2020","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"4","key":"10.1016\/j.jtos.2025.07.010_bib63","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/1120672118791936","article-title":"Safety and tolerability of lifitegrast ophthalmic solution 5.0%: pooled analysis of five randomized controlled trials in dry eye disease","volume":"29","author":"Nichols","year":"2019","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2025.07.010_bib64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/OPTH.S152841","article-title":"Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a phase III randomized controlled trial","volume":"12","author":"Nichols","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"10.1016\/j.jtos.2025.07.010_bib65","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s12325-015-0273-6","article-title":"Results of a multicenter, randomized, double-masked, placebo-controlled clinical study of the efficacy and safety of visomitin eye drops in patients with dry eye syndrome","volume":"32","author":"Brzheskiy","year":"2015","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.jtos.2025.07.010_bib66","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12325-015-0274-5","article-title":"SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model","volume":"33","author":"Petrov","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2025.07.010_bib67","article-title":"Safety and efficacy of ophthalmic mitochondrial reactive oxygen species scavenger Visomitin for the treatment of dry eye disease: findings of VISTA-1 and VISTA-2 studies [abstract]","volume":"63","author":"Ousler","year":"2022","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.jtos.2025.07.010_bib68","first-page":"1004","article-title":"Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sj\u00f6gren syndrome","volume":"43","author":"Arg\u00fceso","year":"2002","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2025.07.010_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107724","article-title":"Ocular mucins in dry eye disease","volume":"186","author":"Portal","year":"2019","journal-title":"Exp Eye Res"},{"issue":"10","key":"10.1016\/j.jtos.2025.07.010_bib70","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","article-title":"Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial","volume":"119","author":"Matsumoto","year":"2012","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.jtos.2025.07.010_bib71","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","article-title":"Diquafosol ophthalmic solution phase 3 study G. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients","volume":"96","author":"Takamura","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.jtos.2025.07.010_bib72","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/eye.2012.166","article-title":"Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study","volume":"26","author":"Kamiya","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jtos.2025.07.010_bib73","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s12325-014-0162-4","article-title":"Clinical usefulness of diquafosol for real-world dry eye patients: a prospective, open-label, non-interventional, observational study","volume":"31","author":"Yamaguchi","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2025.07.010_bib74","first-page":"2251","article-title":"Real-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, Meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study","volume":"9","author":"Yamaguchi","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"10.1016\/j.jtos.2025.07.010_bib75","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/bjophthalmol-2014-306084","article-title":"A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore","volume":"99","author":"Gong","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2025.07.010_bib76","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1097\/OPX.0000000000000657","article-title":"Comparison of topical cyclosporine and diquafosol treatment in dry eye","volume":"92","author":"Yang","year":"2015","journal-title":"Optom Vis Sci"},{"issue":"2","key":"10.1016\/j.jtos.2025.07.010_bib77","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12325-019-01188-x","article-title":"Long-term safety and effectiveness of diquafosol for the treatment of dry eye in a real-world setting: a prospective observational study","volume":"37","author":"Ohashi","year":"2020","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.jtos.2025.07.010_bib78","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.18240\/ijo.2021.10.07","article-title":"Clinical effectiveness of diquafosol ophthalmic solution 3% in Korean patients with dry eye disease: a multicenter prospective observational study","volume":"14","author":"Eom","year":"2021","journal-title":"Int J Ophthalmol"},{"issue":"10","key":"10.1016\/j.jtos.2025.07.010_bib79","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/jop.2022.0031","article-title":"Effectiveness of topical cyclosporin A 0.1%, diquafosol tetrasodium 3%, and their combination, in dry eye disease","volume":"38","author":"Eom","year":"2022","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2025.07.010_bib80","article-title":"3% diquafosol sodium eye drops in Chinese patients with dry eye: a phase IV study","volume":"10","author":"Wang","year":"2023","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.jtos.2025.07.010_bib81","first-page":"96","article-title":"Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye mode","volume":"42","author":"Fujihara","year":"2001","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.jtos.2025.07.010_bib82","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/10807680260218524","article-title":"INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model","volume":"18","author":"Fujihara","year":"2002","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"12","key":"10.1016\/j.jtos.2025.07.010_bib83","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","article-title":"Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study","volume":"119","author":"Kinoshita","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.jtos.2025.07.010_bib84","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","article-title":"A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye","volume":"120","author":"Kinoshita","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jtos.2025.07.010_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13121-9","article-title":"A prospective, randomized trial of two mucin secretogogues for the treatment of dry eye syndrome in office workers","volume":"7","author":"Shimazaki","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jtos.2025.07.010_bib86","first-page":"86","article-title":"A comparative study between efficacy of cyclosporine 0.1% and rebamipide 2% eye drops in moderate to severe dry eye cases","volume":"7","author":"Patil","year":"2019","journal-title":"J Adv Med Dent Sci Res"},{"issue":"2","key":"10.1016\/j.jtos.2025.07.010_bib87","first-page":"84","article-title":"Comparison of 2% rebamipide and 0.1% sodium hyaluronate in the treatment of dry eye","volume":"23","author":"Sharma","year":"2021","journal-title":"JK Sci"},{"issue":"4","key":"10.1016\/j.jtos.2025.07.010_bib88","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.4103\/IJO.IJO_2586_22","article-title":"Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre","volume":"71","author":"Jain","year":"2023","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2025.07.010_bib89","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/01.ico.0000126436.25751.fb","article-title":"Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model","volume":"23","author":"Urashima","year":"2004","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.jtos.2025.07.010_bib90","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jop.2011.0142","article-title":"Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells","volume":"28","author":"Takeji","year":"2012","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"9","key":"10.1016\/j.jtos.2025.07.010_bib91","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/ICO.0000000000002622","article-title":"A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease","volume":"40","author":"Tauber","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2025.07.010_bib92","first-page":"331","article-title":"Effects of perfluorohexyloctane on signs and symptoms of dry eye disease: SEECASE-1: subgroup analysis based on baseline characteristics [abstract]","volume":"61","author":"Sall","year":"2020","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.jtos.2025.07.010_bib93","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","article-title":"NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study","volume":"130","author":"Tauber","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2025.07.010_bib94","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ajo.2023.03.008","article-title":"NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study","volume":"252","author":"Sheppard","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2025.07.010_bib95","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/ICO.0000000000003418","article-title":"Long-term safety and efficacy of perfluorohexyloctane ophthalmic solution for the treatment of patients with dry eye disease: the KALAHARI study","volume":"43","author":"Protzko","year":"2024","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.jtos.2025.07.010_bib96","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamaophthalmol.2023.0270","article-title":"Perfluorohexyloctane eye drops for dry eye disease associated with Meibomian gland dysfunction in Chinese patients: a randomized clinical trial","volume":"141","author":"Tian","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"1\u20132","key":"10.1016\/j.jtos.2025.07.010_bib97","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2018.01.019","article-title":"Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs","volume":"538","author":"Agarwal","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jtos.2025.07.010_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2023.100704","article-title":"In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease","volume":"98","author":"Vittitow","year":"2023","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.jtos.2025.07.010_bib99","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtos.2021.12.007","article-title":"A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: the MYSTIC study","volume":"24","author":"Quiroz-Mercado","year":"2022","journal-title":"Ocul Surf"},{"issue":"10","key":"10.1016\/j.jtos.2025.07.010_bib100","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/ICO.0000000000002941","article-title":"ONSET-1 phase 2b randomized trial to evaluate the safety and efficacy of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease","volume":"41","author":"Wirta","year":"2022","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.jtos.2025.07.010_bib101","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","article-title":"Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial","volume":"129","author":"Wirta","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2025.07.010_bib102","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.2147\/OPTH.S383091","article-title":"OC-01 (varenicline solution) nasal spray demonstrates consistency of effect regardless of age, race, ethnicity, and artificial tear use","volume":"16","author":"Epitropoulos","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"10.1016\/j.jtos.2025.07.010_bib103","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.clinthera.2022.09.013","article-title":"Bilateral effect of OC-01 (varenicline solution) nasal spray for treatment of signs and symptoms in individuals with mild, moderate, and severe dry eye disease","volume":"44","author":"Katz","year":"2022","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.jtos.2025.07.010_bib104","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40123-022-00607-7","article-title":"Does menopausal status affect dry eye disease treatment outcomes with OC-01 (varenicline solution) nasal spray? A post hoc analysis of ONSET-1 and ONSET-2 clinical trials","volume":"12","author":"Nijm","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"10.1016\/j.jtos.2025.07.010_bib105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/OPX.0000000000001986","article-title":"Does dry eye disease severity impact efficacy of varenicline solution nasal spray on sign and symptom treatment outcomes?","volume":"100","author":"Sheppard","year":"2023","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.jtos.2025.07.010_bib106","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jtos.2022.05.001","article-title":"Nicotinic acetylcholine receptor stimulation: a new approach for stimulating tear secretion in dry eye disease","volume":"25","author":"Pflugfelder","year":"2022","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2025.07.010_bib107","article-title":"Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease","volume":"2023","author":"Hauswirth","year":"2023","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.jtos.2025.07.010_bib108","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/cxo.12910","article-title":"Effects of intranasal administration of violet oil in dry eye disease","volume":"102","author":"Saffar Shahroodi","year":"2019","journal-title":"Clin Exp Optom"},{"issue":"2","key":"10.1016\/j.jtos.2025.07.010_bib109","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3892\/etm.2020.8838","article-title":"Intense pulsed light for the treatment of Meibomian gland dysfunction: a systematic review and meta-analysis","volume":"20","author":"Liu","year":"2020","journal-title":"Exp Ther Med"},{"issue":"5","key":"10.1016\/j.jtos.2025.07.010_bib110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/ICO.0000000000003400","article-title":"Safety and efficacy of topical vitamin D in the management of dry eye disease associated with Meibomian gland dysfunction: a placebo-controlled double-blind randomized controlled trial","volume":"43","author":"Hassanpour","year":"2024","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2025.07.010_bib111","article-title":"Homoeopathic eye drops in the treatment of mild-to-moderate dry eye disease: randomised, prospective, multicentre, single-masked study","author":"Mortemousque","year":"2023","journal-title":"Eur J Ophthalmol"},{"issue":"12","key":"10.1016\/j.jtos.2025.07.010_bib112","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/02713683.2019.1641824","article-title":"Efficacy and safety of topical chloroquine in mild to moderate dry eye disease","volume":"44","author":"Titiyal","year":"2019","journal-title":"Curr Eye Res"},{"issue":"4","key":"10.1016\/j.jtos.2025.07.010_bib113","first-page":"91","article-title":"Single blind, prospective, comparative assessment of the efficacy of chloroquine phosphate 0.03% and sodium carboxymethyl cellulose 1% in dry eye","volume":"14","author":"Singh","year":"2022","journal-title":"Int J Pharm Clin Res"},{"issue":"6","key":"10.1016\/j.jtos.2025.07.010_bib114","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/cxo.12524","article-title":"Randomised controlled trial of topical antibacterial Manuka (Leptospermum species) honey for evaporative dry eye due to Meibomian gland dysfunction","volume":"100","author":"Albietz","year":"2017","journal-title":"Clin Exp Optom"},{"issue":"6","key":"10.1016\/j.jtos.2025.07.010_bib115","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/bjophthalmol-2020-317506","article-title":"Randomised assessor - masked trial evaluating topical manuka honey (Optimel) in treatment of meibomian gland dysfunction","volume":"106","author":"Li","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"13","key":"10.1016\/j.jtos.2025.07.010_bib116","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.3760\/cma.j.issn.0366-6999.20140048","article-title":"Clinical efficacy of 0.1% pranoprofen in treatment of dry eye patients: a multicenter, randomized, controlled clinical trial","volume":"127","author":"Chen","year":"2014","journal-title":"Chin Med J"},{"key":"10.1016\/j.jtos.2025.07.010_bib117","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2334077","article-title":"Cyclosporine (0.05%) combined with diclofenac sodium eye drops for the treatment of dry eye disease","volume":"2022","author":"Bai","year":"2022","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jtos.2025.07.010_bib118","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/DDDT.S207743","article-title":"An updated systematic review with meta-analysis of randomized trials on topical cyclosporin A for dry-eye disease","volume":"14","author":"Tuan","year":"2020","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jtos.2025.07.010_bib119","series-title":"Presented at: tear film and ocular surface society (TFOS) 2024 conference; October 30\u2013November 2","article-title":"Safety of lifitegrast in patients with dry eye disease: analysis of a postmarketing database","author":"Quint","year":"2024"},{"issue":"6","key":"10.1016\/j.jtos.2025.07.010_bib120","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s40271-022-00586-8","article-title":"Patient medication preferences for managing dry eye disease: the importance of medication side effects","volume":"15","author":"Ozdemir","year":"2022","journal-title":"Patient"},{"issue":"12","key":"10.1016\/j.jtos.2025.07.010_bib121","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.ophtha.2023.07.009","article-title":"Thermal pulsation in the management of meibomian gland dysfunction and dry eye","volume":"130","author":"Tao","year":"2023","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.jtos.2025.07.010_bib122","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.3390\/jcm12083039","article-title":"Intense pulsed light therapy in the treatment of dry eye diseases: a systematic review and meta-analysis","volume":"12","author":"Demolin","year":"2023","journal-title":"J Clin Med"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012425000989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012425000989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T10:00:17Z","timestamp":1764756017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012425000989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":122,"alternative-id":["S1542012425000989"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2025.07.010","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical pharmacologic treatments for dry eye disease: A systematic review","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2025.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}